Non-selective histone deacetylase (HDAC) inhibitors restore spine impairment and memory function (Fischer et al., 2007; Ricobaraza et al., 2012), suggesting that HDAC inhibitors are one of the candidates to develop AD therapies that could have disease-modifying effects. The gene discussed is HDAC9; the disease is Alzheimer disease.